在中度至重症牛皮症中成功降低塞库金纽马布剂量的预测因素:一项回顾性研究
Jiawen Chen1,2,3,4, Zhixun Xiao1,2,3,4, Xueting Zeng1,2,3,4
1Department of Dermatology, the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Psoriasis (Auckland, N.Z.)
|October 24, 2025
概括
在牛皮患者中,成功的sequinumab剂量逐渐减少与较低的BMI和在温暖的月份开始治疗有关. 这一策略可能有助于保持疾病控制,同时降低成本和副作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮 (PsO) 是一种常见的慢性皮肤疾病,影响全球数百万人.
- 生物疗法,如seukinumab,是有效的管理中度至重度的斑块性牛皮.
- 通过剂量逐渐降低策略优化secokinumab治疗是一个新兴的临床挑战.
研究的目的:
- 在中度至重度斑块性牛皮的患者中,确定secukinumab剂量逐渐减少成功的关键预测因子.
- 分析影响降低seukinumab剂量方案的疗效和安全性的因素.
- 为个性化牛皮治疗管理提供基于证据的见解.
主要方法:
- 对75名中度至重度斑块性牛皮患者的回顾性分析,这些患者接受了300毫克的secukinumab治疗.
- 患者在逐渐减少之前至少6个月达到并保持了90的牛皮区域和严重程度指数 (PASI).
- 统计方法包括曼-惠特尼U测试,弗里德曼M测试和后勤回归 (P<0.05).
主要成果:
- 超过一半 (53.33%) 的患者成功地逐渐减少了secukinumab的剂量.
- 成功逐渐减少的重要预测因素包括较低的体重指数 (BMI),剂量减少的时间和逐渐减少前治疗的持续时间.
- 观察到季节性变化,在秋季和冬季尝试逐渐缩小时,故障率更高.
结论:
- 较低的BMI,在春季/夏季开始逐渐减少剂量,并实现快速的PASI 90反应与成功的sequinumab剂量减少有关.
- 在特定的临床条件下,逐渐降低secukinumab剂量似乎可行,以保持疾病控制.
- 这种方法可能有助于降低治疗成本和尽量减少不良影响.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
148
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
148
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
218
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
218